新诺威子公司司库奇尤单抗注射液III期临床试验获得顶线分析数据

Core Viewpoint - New Horizon (300765.SZ) announced that its subsidiary, Giant Biopharmaceutical Co., Ltd., has achieved positive topline results in the Phase III clinical trial of its drug, Tislelizumab injection, demonstrating clinical equivalence to the reference drug, Cosentyx [1] Group 1: Product Development - The drug Tislelizumab is a fully human IgG1 monoclonal antibody and a biosimilar to Cosentyx [1] - Cosentyx has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] Group 2: Clinical Trial Results - The key study met its predefined primary endpoint and showed positive topline results [1] - Statistical analysis indicates that Tislelizumab has clinical equivalence to Cosentyx, with good safety profiles and no new or unexpected safety signals [1] - The drug is expected to meet the long-term safety needs of patients [1]